Amgen | AMGN

Stock Price
383.74
Daily Change
-7.53 -1.92%
Monthly
-7.38%
Yearly
35.73%
Q3 Forecast
427.92

EPS Reference Time Actual Consensus Previous
2026-11-03 FY2026Q3 PM 5.76 5.64
2026-08-04 FY2026Q2 PM 6.29 5.59 6.02
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58



Peers Price Chg Day Year Date
Takeda 5,657.00 42.00 0.75% 25.60% Sep/10
AbbVie 253.96 3.05 1.22% 15.32% Sep/10
Agios Pharmaceuticals 33.59 -1.04 -3.00% -5.86% Sep/10
ALKERMES 45.60 0.20 0.43% 69.31% Sep/10
Amgen 383.74 -7.53 -1.92% 35.73% Sep/10
Biogen 215.47 4.74 2.25% 44.77% Sep/10
BioMarin Pharmaceutical 65.45 1.04 1.61% 17.06% Sep/10
Bristol-Myers Squibb 63.98 -0.43 -0.67% 34.58% Sep/10
Coherus Biosciences 1.34 0.02 1.52% 0.75% Sep/10
Exelixis 57.72 -0.61 -1.05% 47.73% Sep/10

Indexes Price Day Year Date
US500 7593 -43.31 -0.57% 15.27% Sep/10
USND 26086 -166.94 -0.64% 18.34% Sep/10
US30 52023 -357.85 -0.68% 12.83% Sep/10
US100 29158 -263.48 -0.90% 21.53% Sep/10

Amgen traded at $381.88 this Thursday September 10th, decreasing $9.39 or 2.40 percent since the previous trading session. Looking back, over the last four weeks, Amgen lost 7.83 percent. Over the last 12 months, its price rose by 35.07 percent. Looking ahead, we forecast Amgen to be priced at 427.92 by the end of this quarter and at 401.15 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Stock Price Hits 4-week Low
Amgen shares decreased to 407.08 USD, the lowest since August 2026. Over the past 4 weeks, Amgen gained 0.05%, and in the last 12 months, it increased 43.85%.
2026-09-08
Amgen Stock Price Hits 11-week High
Amgen shares increased to 358.73 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.78%, and in the last 12 months, it increased 28.52%.
2026-06-25
Amgen Stock Price Hits 5-week High
Amgen shares increased to 345.87 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.8%, and in the last 12 months, it increased 20.51%.
2026-06-04